Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists (GIP/GLP-1 RAs) are emerging as effective treatments for obesity and cardiometabolic disease. This study evaluated physician perceptions of the safety and efficacy of semagl...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Journal of Cardiovascular Development and Disease |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2308-3425/12/1/19 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588274690949120 |
|---|---|
| author | Srikanth Krishnan Pratyaksh K. Srivastava Jayram Attaluri Rebecca Nayeri Dhananjay Chatterjee Jay Patel Ali Nsair Matthew Budoff Arash Nayeri |
| author_facet | Srikanth Krishnan Pratyaksh K. Srivastava Jayram Attaluri Rebecca Nayeri Dhananjay Chatterjee Jay Patel Ali Nsair Matthew Budoff Arash Nayeri |
| author_sort | Srikanth Krishnan |
| collection | DOAJ |
| description | Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists (GIP/GLP-1 RAs) are emerging as effective treatments for obesity and cardiometabolic disease. This study evaluated physician perceptions of the safety and efficacy of semaglutide and tirzepatide through a questionnaire administered to 165 attending physicians specializing in internal or family medicine, with 122 responses received. Physicians reported an average patient weight loss of 9.22%, significantly lower than the 14.9% and 18.5% reported in the STEP and SURMOUNT trials, respectively. Estimated side effect rates (32.62%) were markedly lower than trial-reported rates (89.7% and 80.5%), while estimated discontinuation rates (8.59%) exceeded trial data. Cardiovascular benefits were perceived by 48.4% of physicians in diabetic patients, consistent with random guessing, and by only 39.3% in nondiabetic patients, significantly below random guessing expectations. These results highlight discrepancies between physician perceptions and clinical evidence, suggesting gaps in understanding regarding these agents’ efficacy and safety profiles. Addressing these gaps could enhance physician knowledge, patient adherence, and clinical outcomes. |
| format | Article |
| id | doaj-art-5ad2e11ab76a46d29db506362f362fcc |
| institution | Kabale University |
| issn | 2308-3425 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Cardiovascular Development and Disease |
| spelling | doaj-art-5ad2e11ab76a46d29db506362f362fcc2025-01-24T13:36:00ZengMDPI AGJournal of Cardiovascular Development and Disease2308-34252025-01-011211910.3390/jcdd12010019Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical EvidenceSrikanth Krishnan0Pratyaksh K. Srivastava1Jayram Attaluri2Rebecca Nayeri3Dhananjay Chatterjee4Jay Patel5Ali Nsair6Matthew Budoff7Arash Nayeri8The Lundquist Institute at Harbor-UCLA, Torrance, CA 90502, USADepartment of Medicine, Division of Cardiology, University of California Los Angeles, Los Angeles, CA 90095, USAFaculty of Life Sciences & Medicine, Kings College London, London SE1 9NH, UKDepartment of Medicine, Division of Hematology-Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USADepartment of Medicine, Division of Cardiology, University of California Los Angeles, Los Angeles, CA 90095, USADepartment of Medicine, Division of Cardiology, University of California Los Angeles, Los Angeles, CA 90095, USADepartment of Medicine, Division of Cardiology, University of California Los Angeles, Los Angeles, CA 90095, USAThe Lundquist Institute at Harbor-UCLA, Torrance, CA 90502, USACedars Sinai Medical Center, Los Angeles, CA 90048, USAGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists (GIP/GLP-1 RAs) are emerging as effective treatments for obesity and cardiometabolic disease. This study evaluated physician perceptions of the safety and efficacy of semaglutide and tirzepatide through a questionnaire administered to 165 attending physicians specializing in internal or family medicine, with 122 responses received. Physicians reported an average patient weight loss of 9.22%, significantly lower than the 14.9% and 18.5% reported in the STEP and SURMOUNT trials, respectively. Estimated side effect rates (32.62%) were markedly lower than trial-reported rates (89.7% and 80.5%), while estimated discontinuation rates (8.59%) exceeded trial data. Cardiovascular benefits were perceived by 48.4% of physicians in diabetic patients, consistent with random guessing, and by only 39.3% in nondiabetic patients, significantly below random guessing expectations. These results highlight discrepancies between physician perceptions and clinical evidence, suggesting gaps in understanding regarding these agents’ efficacy and safety profiles. Addressing these gaps could enhance physician knowledge, patient adherence, and clinical outcomes.https://www.mdpi.com/2308-3425/12/1/19GIP GLP-1 receptor agonistmetabolic syndromeobesityweight losssemaglutidetirzepatide |
| spellingShingle | Srikanth Krishnan Pratyaksh K. Srivastava Jayram Attaluri Rebecca Nayeri Dhananjay Chatterjee Jay Patel Ali Nsair Matthew Budoff Arash Nayeri Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence Journal of Cardiovascular Development and Disease GIP GLP-1 receptor agonist metabolic syndrome obesity weight loss semaglutide tirzepatide |
| title | Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence |
| title_full | Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence |
| title_fullStr | Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence |
| title_full_unstemmed | Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence |
| title_short | Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence |
| title_sort | physician perceptions of the safety and efficacy of glp 1 receptor agonists underestimation of cardiovascular risk reduction and discrepancies with clinical evidence |
| topic | GIP GLP-1 receptor agonist metabolic syndrome obesity weight loss semaglutide tirzepatide |
| url | https://www.mdpi.com/2308-3425/12/1/19 |
| work_keys_str_mv | AT srikanthkrishnan physicianperceptionsofthesafetyandefficacyofglp1receptoragonistsunderestimationofcardiovascularriskreductionanddiscrepancieswithclinicalevidence AT pratyakshksrivastava physicianperceptionsofthesafetyandefficacyofglp1receptoragonistsunderestimationofcardiovascularriskreductionanddiscrepancieswithclinicalevidence AT jayramattaluri physicianperceptionsofthesafetyandefficacyofglp1receptoragonistsunderestimationofcardiovascularriskreductionanddiscrepancieswithclinicalevidence AT rebeccanayeri physicianperceptionsofthesafetyandefficacyofglp1receptoragonistsunderestimationofcardiovascularriskreductionanddiscrepancieswithclinicalevidence AT dhananjaychatterjee physicianperceptionsofthesafetyandefficacyofglp1receptoragonistsunderestimationofcardiovascularriskreductionanddiscrepancieswithclinicalevidence AT jaypatel physicianperceptionsofthesafetyandefficacyofglp1receptoragonistsunderestimationofcardiovascularriskreductionanddiscrepancieswithclinicalevidence AT alinsair physicianperceptionsofthesafetyandefficacyofglp1receptoragonistsunderestimationofcardiovascularriskreductionanddiscrepancieswithclinicalevidence AT matthewbudoff physicianperceptionsofthesafetyandefficacyofglp1receptoragonistsunderestimationofcardiovascularriskreductionanddiscrepancieswithclinicalevidence AT arashnayeri physicianperceptionsofthesafetyandefficacyofglp1receptoragonistsunderestimationofcardiovascularriskreductionanddiscrepancieswithclinicalevidence |